News & Analysis on Clinical Trial Services & Contract Research And Development
A UK university has joined forces with a major pharmaceutical company in a unique collaboration, worth £2.5 million (€3.6 million) ensuring drug researchers of the future will be trained in 'magic bullet' drug R&D, which has been hailed as the next...
ARTEL announces a new laboratory innovation to improve the performance of automated liquid handlers, introducing a system capable of verifying multichannel instrumentation using non-aqueous test solutions, such as Dimethyl Sulfoxide (DMSO).
Evotec has announced the successful completion of the single ascending dose component of its phase I trial for its subtype-specific NMDA receptor antagonist drug candidate for the treatment of Alzheimer's disease.
Affymetrix and Iconix have formed a collaboration to develop new solutions for assessing the toxicological and pharmacological properties of drugs and drug candidates.
Cardinal health experienced a 42 per cent jump in quarterly profit, helped by renewed growth in its drug distribution and sterile manufacturing operations, which have both experienced problems that dragged down earnings in previous quarters. The...
Outsourcing-Pharma: Focus on Phase IIIB-IV research
The spate of recent high-profile drug recalls, culminating in the dramatic high profile withdrawal of Vioxx in 2004, has fuelled a trend of consolidation within the Phase IIIB-IV clinical trials outsourcing sector that looks set to continue strangling...
Molecular Devices has launched its proprietary system, which offers Fluorescence Polarisation (FP) and Time Resolved Fluorescence Resonance Energy Transfer (TR-FRET) detection, allowing researchers to select between these two well-known detection...